Introduction
Resistance to antiepileptic drugs (AEDs) affects approximately 30% of patients with epilepsy. In addition to potential causes of apparent resistance such as poor drug compliance or suboptimal dosing, several clinical features like early seizure onset, length of seizure history before treatment, or several pathologic characteristics such as hippocampal sclerosis and severe brain injury have been associated with a high rate of drug resistance. 1 Progress in epilepsy research has shown that genetic variations can affect responsiveness to AEDs. The multidrug-resistance 1 (MDR1) gene product Pglycoprotein is of particular interest, and was first identified in cancer cells as a protein responsible for resistance to many drugs. 2 P-glycoprotein is expressed in normal tissues, where it performs a defensive role against potentially toxic substances in intestinal cells, renal proximal tubule cells, and in the endothelial cells of the brain capillary endothelium.
3 MDR1 is highly polymorphic and the 'apparently silent' C3435T polymorphism in exon 26 has been correlated with the expression of P-glycoprotein. Summary The variability of P-glycoprotein expression in individuals is linked to a C3435T polymorphism of the multidrug-resistance 1 (MDR1) gene, and the CC genotype at the C3435T polymorphism was reported to be associated with multidrug resistance in epilepsy patients. Since population frequencies of polymorphic genes depend on ethnic specificity, we investigated functional significance of the C3435T polymorphism of the MDR1 gene in Korean epilepsy patients. One hundred and eight patients with drug-responsive epilepsy, 63 patients with drug-resistant epilepsy, and 219 control migraine subjects were studied, but the analysis for C3435T allele showed no significant association between the CC genotype and the multidrug-resistant epilepsy. We suggest that influence of the C3435T polymorphism in the multidrugresistant epilepsy may not be significant in Korean populations and further investigations in various ethnic populations would be necessary to clarify the effect of C3435T polymorphism on the mutidrug resistance in epilepsy patients. # 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
People homozygous for the C allele have on average substantially higher P-glycoprotein expressions than those homozygous for the T allele. 4 With regards to epilepsy treatment, P-glycoprotein can transport many AEDs of different action mechanisms, 5 and the increased expression of P-glycoprotein was found in the brain specimens of those with intractable epilepsy. 6, 7 Recently, it has been documented that patients with drug-resistant epilepsy are more likely to have the CC genotype at the C3435T polymorphism than those with drug-responsive epilepsy, 8 and several conflicting reports [9] [10] [11] have been published regarding confirmation of the previous report.
Population frequencies of many polymorphic genes of pharmacogenetic interest depend on ethnic specificity. Association of these genes with inter-individual differences in drug effectiveness and drug toxicity may also depend on the ethnic characteristics of a population. 12 Since the C3435T polymorphism has been detected in various ethnic populations with considerable ethnic variation in frequency, 13 we studied the allele frequencies of the C3435T polymorphism with drug-responsive or drug-resistant epilepsy.
Methods Subjects
Patients were consecutively recruited through the epilepsy clinic at Seoul National University Hospital. Drug-resistant or drug-responsive epilepsy were determined according to the following criteria. Drug resistance was defined as the occurrence of at least four seizures over the year before recruitment with trials of more than three antiepileptic medications at maximal tolerated doses, which were established by the occurrence of clinical side effects at supramaximal doses.
Drug responsiveness was defined as complete seizure freedom for at least an year, up to the date of the last follow-up visit. Control subjects were individuals with migraine without a history of epilepsy. All epilepsy and control patients were ethnically homogeneous Koreans. We analyzed 108 patients with drug-responsive epilepsy, 63 patients with drug-resistant epilepsy, and 219 control patients. The demographic characteristics of subjects are listed in Table 1 .
Identification of MDR1 polymorphisms
Blood samples (5 ml) were collected in EDTA vacutainer tubes for DNA extraction and MDR1 genotyping. Purified genomic DNA was extracted from peripheral blood leukocytes using the phenolchloroform extraction method. Genotyping was conducted using an ABI 7700 sequence Detection System, or ''Taqman'' TM assay (Applied Biosystems). Polymerase chain reaction (PCR) primers and probes were designed using Primer Express TM software (Applied Biosystems). Assay design and conditions were based on the allelic discrimination protocol supplied by Applied Biosystems. The cDNA 3435C allele probe was labeled on the 5 0 end with the FAM receptor dye and contained the following nucleotide sequence 5 0 -CAAGATCCATCCCGACC-3 0 . The cDNA 3435T allele probe was labeled on the 5 0 end with the VIC receptor dye and contained the following nucleotide sequence 5 0 -CAAGATCCATTCCGACC-3 0 . Forward and reverse primers were used to amplify the region surrounding the C3435T polymorphism. The nucleotide sequence of the forward primer was 5 0 -TCTTCTTTGCTCCT-CCATTGC-3 0 and of the reverse primer was 5 0 -TGAGCTGCGGTTTCTCTTCA-3 0 . PCR reactions were performed in a reaction volume 15.0 ml using the hot-start format. The reaction components were as follows: 2X Taqman Universal PCR Master Mix, 600 nM of each primer, 100 nM of each probe, and 20 ng of genomic DNA. PCRs were run on a Perkin Elmer GenAmp 1 9700 thermocycler using the 9600 mode under the following conditions: 50 8C for 2 min (AmpErase 1 UNG activation), 95 8C for 10 min (AmpliTaq Gold Activation), followed by 50 cycles of 92 8C for 15 s (denaturation) and 60 8C for 1 min (annealing/extension). Samples that could not be scored were repeated. Unreadable results on the second run were scored as undetermined (n = 17: 11 cases, 6 controls). We repeated the ''Taqman'' TM assay on 10% of the samples.
Results
Demographic characteristics showed that the male to female sex ratio in the drug-responsive group was higher than in the drug-resistant group, but this result failed to achieve statistical significance ( p = 0.130 by x 2 test). There was no age difference between the drug-responsive and drug-resistant groups. In patients with drug-responsive epilepsy (N = 101), genotypic frequencies were 47.5% CC, 29.7% CT, and 22.8% TT. In patients with drug-resistant epilepsy (N = 59), 32.2% CC, 45.8% CT, and 30.1% TT. In control subjects with migraine (N = 213), 41.5% CC, 43.4% CT, and 15.1% TT. There was no significant difference in genotype or allele frequencies between groups ( p > 0.05, by x 2 test, Table 2 ).
Discussion
The mechanisms of drug resistance in epilepsy have not been established. Hippocampal sclerosis is frequently related to drug resistance in patients with mesial temporal epilepsy. However, whether hippocampal sclerosis is the cause or the consequence of chronic epileptic seizures and drug resistance is unknown. Channelopathy has been considered, but has been found in only a limited number of cases with a strong familial tendency. Many patients resistant to AED treatment are resistant to a broad range of AEDs with different actions, and resistance occurs across a wide variety of epilepsy types. The functional characteristics of non-specific drug transporter proteins could explain broader resistance across types of epilepsy and to a range of AEDs.
14 Polymorphisms of MDR1 gene alter in vivo transport activity for various drugs, and a C3435T polymorphism has been most frequently reported to be associated with alterations in disposition kinetics of various clinically useful drugs. 15 However, in our study, no significant association was found between the C3435T polymorphism and response to AED treatment. The reason for the contradictory results to the initial report 8 is unclear. The small sample size in the present study may be responsible for the negative result. In genetic association studies, initial positive studies tend to overestimate effect size and subsequent replication attempts require larger sample size. 16 It is also possible that the inconsistent reports result from the ethnic difference in linkage disequilibrium. There may be inter-population difference in the degree of linkage disequilibrium between the C3435T polymorphism and disease alleles, and studies in different ethnic groups may cause different associations. Nevertheless, our study may be a true negative result and show that the influence of C3435T polymorphism in multidrug resistance is not significant in Korean populations, because the drug resistance in epilepsy is dependent of the effects of many biologic and genetic risk factors, and the functional implication of one factor for drug resistance might be variable in different populations. It may be related with the fact that there are controversies in the effects of the C3435T polymorphism on the expression of P-glycoprotein, 17 and it is still not clear whether some important AEDs such as carbamazepine and valproate are really substrates of P-glycoproprotein. 5, 18 In conclusion, we could not confirm a previously reported association between the C3435T polymorphism and the multidrug-resistant epilepsy in Korean population. Ethnic difference or small sample size may be responsible for our negative result, but it is also possible that the original report was a false positive finding. To clarify the exact clinical implication of the C3435T polymorphism on the multidrug resistance in epilepsy, further investigations in various ethnic populations would be necessary. Additionally, there are other MDR1 genetic variations that were reported to be associated with the increased risk for multidrug resistance in epilepsy, 9, 19 and further replication study in other ethnic groups would also be needed. 
